RxBenefits unveils Patient Assistance program to lower cost of specialty drugs
RxBenefits is debuting two new Patient Assistance solutions. Designed to complement RxBenefits' comprehensive suite of pharmacy solutions, these alternative funding offerings can help reduce specialty drug costs for some patients and plans, the company said.
With these solutions, patients receive their medications, even if alternative funding is unavailable or they don't qualify for need-based assistance, the company said.
[Read more: AAM reacts to Avalere study on generic drug costs]
The solutions can offer substantial savings opportunities in the right situations where other market alternatives fall short. The program upholds the RxBenefits approach, ensuring members have a quality service experience while getting the medications they need based on necessary clinical oversight. In keeping with the company’s client-aligned business model, RxBenefits does not receive any fees or commissions related to these solutions.
"At RxBenefits, we leverage our negotiating power, clinical expertise, and exceptional service to do what’s right for our clients and their members,” said Wendy Barnes, CEO of RxBenefits. “This solution set is just one piece of the specialty management puzzle,” Barnes added. “There is no single solution to managing specialty drug costs. A multi-pronged approach to address both specialty drug spend and volatility is critical to doing what’s right for patients by making specialty drugs more accessible and affordable for them and plan sponsors."
[Read more: Avalere analysis examines Medicare Part D’s plan tier placement of generics]
“Self-funded plans require a comprehensive, layered approach to managing specialty spend, and the utilization of alternative funding is one more way RxBenefits helps self-funded plans save on specialty drugs,” said Mark Campbell, senior vice president of clinical solutions at RxBenefits. “We’re excited to work with our preferred providers to ensure available and appropriate savings are passed along to patients and plans.”